Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Income (2022 - 2025)

Historic Operating Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$53.8 million.

  • Centessa Pharmaceuticals' Operating Income fell 1591.42% to -$53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 3225.86%. This contributed to the annual value of -$201.1 million for FY2024, which is 1738.18% down from last year.
  • Centessa Pharmaceuticals' Operating Income amounted to -$53.8 million in Q3 2025, which was down 1591.42% from -$54.7 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Operating Income high stood at -$30.8 million for Q1 2025, and its period low was -$74.6 million during Q4 2024.
  • Its 4-year average for Operating Income is -$48.3 million, with a median of -$47.0 million in 2023.
  • Its Operating Income has fluctuated over the past 5 years, first soared by 3127.28% in 2023, then plummeted by 11200.75% in 2024.
  • Centessa Pharmaceuticals' Operating Income (Quarter) stood at -$41.6 million in 2022, then grew by 15.44% to -$35.2 million in 2023, then crashed by 112.01% to -$74.6 million in 2024, then grew by 27.88% to -$53.8 million in 2025.
  • Its Operating Income was -$53.8 million in Q3 2025, compared to -$54.7 million in Q2 2025 and -$30.8 million in Q1 2025.